Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is not the first time you have brought this structure up. I would be happy with it but I will believe it when I see it. The same with any deal. I hope this BOD finally bucks up and makes some magic happen. So far they have been MIA.
I hope you are right about knowing shortly about approval of the production facility and more importantly the use of the Flaskworks units, if that happens prior to the Annual Meeting, I think that we will go into the meeting with much higher share prices. If Flaskworks is Internationally approved it shouldn't be long before we have facilities ready for inspection everywhere that they are needed to support regulators approval.
Gary
There will be news before asm. Imo.
Your welcome, its very interesting and enlightening.
PM: Yes, I did not think that through to realize that multiple JVs on the same IP is frought with potential legal issus. Thanks!
Peace.
Since we are going to only 1.7B shares unless the firm anticipates the stock will remain at $25 we don't have enough shares given R&D costs Direct as well as more trials for L. Do you think Merck loves NWBO more than Bristol?
Thanks Lykiri, do you have a link for these statements?
Also, did you watch the video I linked for Dr. Liau’s May 2021 presentation? Do you think she misspoke when she said Bristol Myers Squibb (BMS), or do you believe her plans changed?
They should try an additional arm with Pembrolizumab 100** mg q 6 weeks with the DC and CSF1R combination.
It’s just stupid not to try and reduce toxicity, when they know the combination is synergistic. Pembro toxicity prevents too many people from receiving treatment. Imo.
**Instead of 400mg
Well said Bio as always.
So, the JA, SNO and PR had the stock go backwards but this article will provide more value?
Gotcha!
Kaizan,
My thoughts are that competitive bidding for the C would be more along the lines of a buyout. This appears to be headed to a more structured transaction with multiple partners for JVs.
There are three major deal groupings in play: The ownership rights to L; the partnership rights for L; and everything to do with the rights for Direct. That’s a lot of moving pieces and assets in play. The C has some role in all of that, plus a role in satisfying the price discovery requirements for an immediate listing.
One thought that comes to mind from your question is how do the BP participants involved in JV avoid anti-trust issues. For instance, if Merck and BMY had any discussions related to agreeing separate partnership rather than bidding against one another for a buyout, that might trigger a price fixing isolation. My guess is LP & LG proposed the conceptual structure for multiple partners, then everyone worked from that same sheet of music.
Put it on my watchlist. Thanks!
P5/55
Protocol 020221, Version 6.2
Best wishes to your niece.
I just don’t think NWBO is independently capable of changing their approach speed for future development. Hopefully they’ll either pair up or be acquired as a wholly owned subsidiary.
I assume you are referencing page numbers in the 55 page protocol. That is the final protocol dated 9/23/2020.
They do not have the full protocol history, but summary changes are at the bottom and clear.
I do not care for the woman but voting no is just hurting yourself. If there was a claw back of her bonuses I would vote yes.
Hey Punk,
Are we supposed to be impressed?? Ms. Houser quoted Statnews as her main source!!!
Cheers,
BB
Watching the Gamestop story on Netflix. I highly recommend it since it gets behind the scenes of market manipulation, and how big companies, Citadel, that are short and losing money on a stock can go after individual users. But the opposite does not happen, ala NWBO, showing how the retail investor is almost always a loser when big organizations lose money shorting a stock with false news and want revenge. The show points out what a cluster f#ck that whole process is.
I have the same thoughts. Stat news garbage.
Great post Flip. Unfortunately big pharma has not been on our side and they have the ability to influence the regulatory authorities. But I personally believe the linda's have lined up the dominoes and they have started the show.
I have lost a Nephew now to GBM and I have a Niece that has had one operation with chemotherapy. We need to advance the DCVax platform ASAP!
Unlike many here, I would rather see in depth broad testing of the platform to see what really works and advance the science than a buyout by BP.
The $ will come eventually.
Of course they will have the votes dennisdave. Every time there is a shareholder vote, there’s always a chorus of “vote no” on this message board, but guess what? These critical votes always pass. Northwest Bio may have thousands of novice retail shareholders, but their largest investors are quite savvy, and will certainly support the company at this critical stage. I would bet on it.
Northwest Bio has FINALLY delivered the goods, and I think the pace of events of the past few years is about to accelerate. Those entities that have been fighting against Northwest Bio and have been able to keep the share price depressed, are fighting a losing battle, and their time is running out. These big fish in the little pond are going to discover that there are much, much larger fish out there . . . one might even say whales.
i'm pretty sure livejournal.com is still around, lc, if you want to continue this dialogue with yourself.
have you considered developing some of this prose into a one-man show about NWBO? i believe in you.
exwannabe,
P.5/55
P.11/55
CherryTree1
Re: Johnni post# 539265
Sunday, November 27, 2022 8:28:49 AM
Post#
539326
of 539379
Thanks for posting this.
I sent this email to them per their request at the end of the article:
Dear Ms Houser,
There are important allegations in your article that are wrong.
Namely when you state:
"When the terms of an analysis are defined after results have already been seen, it’s called a “post-hoc analysis,” and it’s a controversial way to assess a treatment’s efficacy. “The more analyses that are done post-hoc, the greater chance of finding results by chance — meaning that they are not true results"
Post-hoc analysis is defined as: "Post hoc in Latin means 'after this'. Simply put, a post-hoc analysis refers to a statistical analysis specified after a study has been concluded and the data collected. A post-hoc test is done to identify exactly which groups differ from each other. Therefore, such tests are also called multiple comparison tests." Post-hoc analysis is also at times called Data dredging -- sometimes referred to as data fishing -- is a data mining practice in which large data volumes are analyzed to find any possible relationships between the data. Data scientists can then form hypotheses about why these relationships exist. That did not happen here.
The analysis for the DCVAX-L Phase-3 trial was not "post-hoc" because the SAP (Statistical Analysis Plan) was updated and submitted before the trial data was unblinded. Updating the SAP is common before unblinding as stated here: "The plan should be reviewed and possibly updated as a result of the blind review of the data and should be finalized before breaking the blind." http://onbiostatistics.blogspot.com/2020/01/pre-specification-and-statistical.html
If you do you Due Diligence you will find your allegation that the SAP was done after data lock is completely incorrect If you review the their October 2020 NWBO press release:
https://nwbio.com/northwest-biotherapeutics-announces-data-lock-of-phase-iii-trial/
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
05 OCT 2020
FOR IMMEDIATE RELEASE
CONTACTS
Dave Innes
804-513-4758
dinnes@nwbio.com
Les Goldman
240-234-0059
lgoldman@nwbio.com
BETHESDA, Md., October 5, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.
With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.
The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.
“We are excited to be so close to the finish line now, after such a long road” commented Linda Powers, the Company’s CEO. “We are hopeful that DCVax®-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer.”
“We are grateful to the independent service firms and the clinical trial sites who have worked so hard to complete the data collection and confirmation during many months of COVID restrictions and challenges,” Ms. Powers continued. “We are also very grateful to our shareholders for their patience and support, which has made all this possible.”
How could the statisticians proceed with analyses of the raw data and prepare summaries of the Trial results without the final SAP?
They couldn't.
. . . and the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who analyze the data with the statisticians in preparation for public announcement and scientific publication would not let them change SAP after all this is done . . . and even if NWBO tried to do that do you think they would remain silent. These panels, boards and committees are put in place to ensure nothing untort/nefarious like data dredging happens. That could happen for even a microsecond. That is why these people were put in place.
I hope you find my comments and feedback helpful
Bullish
BULLISH
Men who are occupied in the restoration of health to other men, by the joint exertion of skill and humanity, are above all the great of the earth. They even partake of divinity, since to preserve and renew is almost as noble as to create.
New brain cancer vaccine completes clinical trial
Northwest Biotherapeutics reports that its new brain cancer vaccine can extend glioblastoma patients’ lives by months or even years.
By Kristin Houser
November 26, 2022
A new brain cancer vaccine can extend some glioblastoma patients’ lives by months or even years, according to its maker — but the design of the company’s trial has some questioning the claims.
The challenge: The standard treatment for glioblastoma — the most aggressive form of brain cancer — starts with surgery to remove as much of the tumor as possible. After that, patients typically undergo chemotherapy and radiation therapy to kill lingering cancer cells.
But even with treatment, the prognosis for glioblastoma isn’t great — the cancer almost always comes back, and patients live an average of just 12 to 18 months after diagnosis.
A brain cancer vaccine: US biotech company Northwest Biotherapeutics has developed a brain cancer vaccine, called DCVax, that’s designed to help a patient’s own immune system target their tumor.
“The vaccine … provides a personalized solution, working with a patient’s immune system.”
Keyoumars Ashkan
To deliver the treatment, doctors remove a special type of immune system cells, called dendritic cells, from a patient’s blood sample. The cells are then mixed with antigens taken from a sample of the patient’s own tumor.
When the dendritic cells are injected back into the patient, they teach the rest of the immune system to recognize and attack the tumor cells.
“The vaccine … provides a personalized solution, working with a patient’s immune system, which is the most intelligent system known to man,” Keyoumars Ashkan, the European chief investigator of a phase 3 DCVax trial, told the Guardian.
The trial: For the trial, more than 300 newly diagnosed glioblastoma patients were treated with either the brain cancer vaccine or a placebo after standard treatment (surgery to remove their tumor, when possible, followed by radiotherapy and chemotherapy).
That is a very typical trial design. But placebo group members whose cancer returned during the course of the trial were also given the option to receive the vaccine.
When the vast majority of the placebo group chose to get the treatment, the researchers had to find a different comparison group, which wasn’t part of the study.
In the end, 13% of all trial participants treated with DCVax lived for more than five years after diagnosis, compared to 5.7% in the comparison group used for the study, which consisted of more than 1,300 patients from the control groups in other, previous glioblastoma trials.
One trial participant lived for more than 8 years after diagnosis.
According to Ashkan, DCVax produced “clear benefits” in patients who typically have a poorer prognosis, such as older people, and it was well-tolerated, too — just five trial participants reported significant adverse effects that might have been related to the treatment.
“The total results are astonishing,” said Ashkan. “The final results of this phase three trial … offer fresh hope to patients battling with glioblastoma.”
The controversy: Not everyone agrees with that assessment — Donald O’Rourke, a professor of neurosurgery at the University of Pennsylvania, who wasn’t involved with the trial, told STAT he found the data to be “unpersuasive,” in part due to how the study was conducted.
Before Northwest Bio decided to offer the treatment to people in their placebo group, it found that the median time it took for tumors to return was 6.2 months in treated trial participants and 7.6 months in untreated participants.
That means tumors came back sooner in people who received the brain cancer vaccine than those who received the placebo.
“The more analyses that are done post-hoc, the greater chance of finding results by chance.”
Merit Cudkowicz
The decision to compare the trial data to external controls wasn’t made until after the trial had already started. When the terms of an analysis are defined after results have already been seen, it’s called a “post-hoc analysis,” and it’s a controversial way to assess a treatment’s efficacy.
“The more analyses that are done post-hoc, the greater chance of finding results by chance — meaning that they are not true results,” Merit Cudkowicz, the chief of neurology at Mass General Hospital, who wasn’t involved in the study, told the ALS Therapy Development Institute.
Linda Liau, principal investigator of the DCVax study, defended the decision to STAT, noting that, because two-thirds of the people in the placebo arm eventually opted to received DCVax, researchers didn’t have enough people left in that group to conduct a traditional, randomized clinical trial.
“Many clinical trials reported in the literature use external case controls, which is just a different level of evidence than the traditional, randomized controlled trials,” she said.
The bottom line: By giving people in the placebo group an opportunity to receive DCVax when their cancer came back, the trial researchers gave them another shot at fighting their deadly disease — but in doing so, the trial ceased to be a simple comparison of treatment and placebo, muddying the results.
Despite the initial results — that showed tumors returned sooner with DCVax — the brain cancer vaccine could still be a worthwhile glioblastoma treatment. It might lead to better outcomes when paired with another treatment, for example, or work particularly well in certain types of cancer patients.
To find out, though, Northwest Bio will need more trials, designed in such a way that the results are indisputable.
We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.
At Freethink, we believe the daily news should inspire people to build a better world. While most media is fueled by toxic politics and negativity, we focus on solutions: the smartest people, the biggest ideas, and the most ground breaking technology shaping the future.
Subscribe for more stories straight to your inbox
NWBO
Northwest Biotherapeutics Inc (QB)
0.895
0.04295 (5.04%)
Volume: 2,843,315
Day Range: 0.855 - 0.927
Bid: 0.865
Ask: There are multiple 10 year survivors in the DCVax trial. The actual doctors that participated in the study have confirmed this. I don’t know exactly how many, but I remember a bare minimum of 5 individuals that have personally expressed this testimony on social media. I would wager it’s around ~20 people if I had to guess.
And by the way, this is utterly unheard of in GBM
Larppis
Re: biosectinvestor post# 538531
Sunday, November 27, 2022 3:29:57 AM
Post#
539311
of 539375
Hey Bio,
Could it be that the Poly-ICLC used in this DCVax+Keytruda+Poly-ICLC combo trial ( https://clinicaltrials.gov/ct2/show/NCT04201873 ) actually is Hiltonol as under the 'Intervention/treatment' section it says;
Drug: Poly ICLC
Given IM
Other Names:
Hiltonol
Poly I:Poly C with Poly-L-Lysine Stabilizer
poly-ICLC
PolyI:PolyC with Poly-L-Lysine Stabilizer
Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose
Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose
Stabilized Polyriboinosinic/Polyribocytidylic Acid
Maybe not any significance in that even if it really is Hiltonol. But anyways I found it even somewhat interesting bit
Re: ATLnsider post# 539290
Sunday, November 27, 2022 1:50:05 AM
Post#
539299
of 539376
Yes she does say that this new SPORE project is with BMS.
Also I thought I had seen these same slides somewhere and, yes it was in this video where LL also presents the Poly-ICLC combo survival data;
At about 6:45 mark she first talks about BMS failed GBM trials.
Then after the Poly-ICLC data (at about 25:55 mark) she goes into those BMS slides from the Mount Sinai video (this WCM video is a more recent one). And at 31:30 she talks about this future combo trial of DC vaccine+Poly-ICLC+PD-1 mAb+CSFi. It would seem that this trial will be with BMS, too.
3 Likes
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170544969
PM: It appears to me that LP is setting up the ability for NWBO to offer opportunities for one or more JVs. Is this what you are seeing?
If so, do you think given the known MRK and BMY trials, that this could set up competitive bidding for the remaining C shares depending upon how stellar each trial results are?
Thanks. Peace.
Companies can not issue Warrants without the Shares already being Authorized although not yet Outstanding. Not sure sure what you were trying to say here.
"We know for a fact that they need to authorize more shares, to cover warrants and options that have funded the company for quite some time and to meet other obligations."
LOL. Okay no worries, I see. Was thinking with all the naked shorting you all claim exist, then it stands to reason JAMA is likely getting hit with all sorts of disputes. Does anyone wonder if one day we'll see one of these??
"Ensuring an Accurate Scientific Record—Retraction and Republication"
https://jamanetwork.com/journals/jama/fullarticle/2752451
So, I'll ask again just out of extreme precaution, is this normal to have just one company employee take on all this responsibility? Where's Liau and the others?
>>Author Contributions: Dr Bosch had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Hey Horse, I never said she was part of Enron's shenanigans, just that her bio never mentions her time there seems a bit disingenuous.
And now Bigger says it's all about Liau's trial. Just as LC said they would eventually claim.
-Research for researches sake feeds the candy store.
freethink article, got some issues... https://www.freethink.com/health/brain-cancer-vaccine
The website ALS TDI defines "Post-Hoc" analysis as this "The act of looking at the data from a trial or other experiment in new ways after the study’s conclusion is called “post-hoc analysis.”
The Endpoint change was in the works well before the trial concluded, thus, Post-Hoc analysis impossible to be considered as to why endpoint was changed.
post-hoc is often used to create new trials based on subgroups found after a trial concludes.
That is what happened in May. They input garbage and put garbage out in more articles.
People gushing over Linda and swearing their fealty should consider her planning on taking on the folks constantly crushing the stock with false claims. As a steward of the share price she has been a failure. Her decisions over the past ten years should be questioned because assets have languished. If I ever got a good explanation I would cut her some slack.
They are asking for questions prior to the ASM. They received quite a few but pretty much only answered the one question she wanted to answer. I expect a change with a partnership. Voting for her to get cheap shares is not on my hit parade. I am not glowing about her.
This article is nothing but lies and misconceptions!! Probably written by Statnews!!!
Just a slightly different perspective.
Even though there is currently a trial for a combination using DCVax-l as the SOC, remember, and this is a slight different way of looking at this, Dr. Pazdur wants commercial mass production of incoming (new) SOC therapies not only to treat patients equitably around the world, but he also wants a manufacturing capability to churn out enough new validated and consistent product in order that large international trials can be conducted.
Having DCVAx-l monotherapy as the standard of care for recurrent GBM provides a reliable and safe comparator that researchers already strongly suspect can be improved upon with a three product combination. DC + CI + CSF1R.
They’ve known this for at least 6 years but have been able to do little about it, because the commercial SOC has/is taken so long to get to market. They have one trial, DC + CI for rGBM, but they already know it will need to be improved upon by also adding CSF1R.
So all these lined up potential cures for people, Aka combination, DCVax-Direct
and hyperactive DCs, are awaiting a base commercial manufacturing market for DCVax-l.
A short cut???
Parallel to Dr. Pazdur’s position that a ramping global SOC must be available, other professionals believe ECA arms can replace or at least bolster therapy development in the future.
However, if DCVax-l is the therapeutic SOC, its RWD and Phase III data will be utilized. In either case, DCVax-l will need to have built up enough data from which to draw comparisons for trials of combinations and other therapies.
I liken the current situation to ships with grain ready to traverse to their destination but instead sit en masse waiting for the OK from higher up.
It’s repulsive how long this is taking, as patients literally die while technology tries to set up a new system that can globally distribute, treat and, beyond that, test for better combinations and other alternatives.
We have to believe everyone is doing their best, but one can’t help sense that the trappings of a material and bureaucratic world slowed this process down at various turns.
Even public advocates have material self sustaining concerns that potentially distract from their mission to push and support.
Here’s hoping this redirected ship avoids the rocks and moves our painfully slow progress toward a more efficient paradigm and open water.
Of course they’ll get a yes vote on everything from me as well. :)
Whenever an article quotes Stat News I immediately discount the due diligence of the author. Quoting the ignorance of a doctor not connected to the trial is just bad journalism.
I’ll second that.
LP will get my “yes” vote on my substantial number of shares. I have believed in her leadership for this entire time, not stopping now. This lady is IVY league educated, has the “eye of the tiger”, kept this business afloat SOMEHOW, against ALL odds, to reap the glory of a SUCCESSFUL Brain Cancer trial!!! and…. Background in merger and acquisition!!!! ALL THAT NEEDS TO BE SAID!!!! GOOOO you little train NWBO! The WORLD Will know!!! SOON.
ATLinsider, I started my GBM quest with TCLN, moved on to PPHM and finally to NWBO.
I am 100% certain this is the real deal and the culmination of my 30 year quest. This will revolutionize cancer treatments for decades!! This week will be epic IMO.
Very nice CherryTree. Thank you.
It is the same argument AF used and it should have been refuted by the company.
Far from fair. Nothing post hoc about the design. The author should have questioned that remark or got Liau’s take on it. Because it is not.
This article is actually pretty fair and gives both sides a fair hearing in the traditional fashion of objective journalism. We’d prefer just a “DCVax-L is awesome!” but a real journalist will not be pumping even if they feel that Dr. Liau is probably right as seems to be the case here.
One link includes mention of the upcoming trial that will combine ATL-DC, PLX3397 and pembrolizumab.
The link that mentions the trial was updated a couple months ago, so I would take that as current.
The trial has not yet been posted on ct.gov, so no idea when, or if, it runs. There are some trials running that combine pembrollizumab and PLX3397.
Followers
|
1649
|
Posters
|
|
Posts (Today)
|
190
|
Posts (Total)
|
726700
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators flipper44 sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |